Nuwellis Inc (NUWE)vsNovartis AG ADR (NVS)
NUWE
Nuwellis Inc
$1.89
-2.07%
HEALTHCARE · Cap: $177,950
NVS
Novartis AG ADR
$159.85
-0.64%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 646416% more annual revenue ($56.69B vs $8.77M). NVS leads profitability with a 22.5% profit margin vs -217.2%. NUWE trades at a lower P/E of 0.0x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NUWE
Hold37
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NUWE.
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$159.85
$67.31 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 26.2% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -657.5% — below average capital efficiency
Earnings declined 99.2%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NUWE
The strongest argument for NUWE centers on P/E Ratio, Price/Book, Debt/Equity. Revenue growth of 26.2% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : NUWE
The primary concerns for NUWE are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
NUWE profiles as a growth stock while NVS is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
NUWE is growing revenue faster at 26.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 37/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nuwellis Inc
HEALTHCARE · MEDICAL DEVICES · USA
Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?